Technology
Health
Pharmaceutical

Citius Pharmaceuticals

$1.28
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (2.42%) Today
-$0.01 (-0.81%) After Hours

Why Robinhood?

You can buy or sell CTXR and other stocks, options, ETFs, and crypto commission-free!

About

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. Read More The company was founded by Ralph Montrone on September 9, 2010 and is headquartered in Cranford, NJ.

Employees
7
Headquarters
Cranford, New Jersey
Founded
2010
Market Cap
22.97M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
151.20K
High Today
$1.29
Low Today
$1.26
Open Price
$1.26
Volume
25.13K
52 Week High
$3.15
52 Week Low
$0.8582

Collections

Technology
Health
Pharmaceutical
2017 IPO
US
North America

News

Yahoo FinanceMay 1

Citius Pharmaceuticals to Present at the ThinkEquity Conference

CRANFORD, N.J., May 1, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will present at the ThinkEquity Conference on Thursday, May 2, 2019 at 8:30AM ET. The conference is being held at The Mandarin Oriental Hotel in New York City. During the conference, Executive Chairman, Mr. Leonard Mazur will be giving the presentation as well as answering questions ...

387
Yahoo FinanceApr 30

Citius Pharmaceuticals Presents Data on Mino-Lok® Showing 98% Clinical Efficacy

The Data Provides Proof of Salvaging Central Venous Catheters Colonized with Highly Virulent Pathogens in Patients with CLABSI/CRBSI CRANFORD, N.J., April 30, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided a report today on the clinical efficacy of Mino-Lok against various pathogens that are encountered in colonized catheters that cause bacteremia, either central line associa...

497
Simply Wall StApr 27

Those Who Purchased Citius Pharmaceuticals (NASDAQ:CTXR) Shares Three Years Ago Have A 97% Loss To Show For It

581
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.